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during the study period. Median follow-up was 9 (IQR: 7–16)
months; 28 (92%) had at least 6 months of clinical follow-up. Serum
alkaline phosphatase activities did not significantly decrease with
vedolizumab therapy (median 268 (IQR: 105–551) IU/L at base-
line versus 249 (IQR: 183–634) IU/L, p=0.9899 at week 30). Of
the 18 patients with an abnormal alkaline phosphatase at baseline
(>120IU/L), 11 (61%) had improvement with treatment. In these
patients, alkaline phosphatase trended down from 475 IU/L (IQR:
241–757) at baseline to 283 IU/L (IQR: 207–658), p=0.267 at week
30 but none of these normalized (Figure 1). Median alkaline phos-
phatase changes remained similar when patients exposed to UDCA
were excluded. Of the 8 patients (31%) with normal alkaline phos-
phatase at baseline, 4 (50%) had a subsequent increase to abnormal
levels by week 30, from a baseline median of 98 IU/L (IQR: 77–102)
to 146 IU/L (IQR: 90–203), p=0.036 at week 30 (Figure 2). No sig-
nificant changes in other liver biochemistries or the Mayo PSC Risk
Score were demonstrated at week 30. 55% of Crohn’s disease and
21% of ulcerative colitis patients achieved clinical remission at week
30. Seven patients (21%) ceased vedolizumab therapy; one for a de-
terioration in liver biochemistry thought to be a drug reaction and
six for IBD primary non-response. Two patients developed ascend-
ing cholangitis but continued vedolizumab.
Conclusions: Vedolizumab therapy in patients with IBD-PSC has lit-
tle overall effect on liver biochemistry, but is safe and does improve
IBD clinical activity. Treatment earlier in the disease course of PSC
and assessment of longer-term exposure of lymphocyte trafficking
blockade in IBD-PSC remains of interest.
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Background: Therapeutic drug monitoring (TDM) measuring drug
trough levels (TL) and antidrug antibodies (ADA) may aid the ther-
apeutic decision in patients with inflammatory bowel disease (IBD)
who loose response to anti-TNF therapy. Our aim was to evaluate the
frequency and predictive factors of loss of response to adalimumab
therapy and the role of the therapeutic drug monitoring to predict
the loss of response in adalimumab treated IBD patients.
Methods: 112 IBD patients (with 214 TDM measurements, CD/UC
84/28, male/female 50/62, mean age CD/UC: 36/35 years, mean du-
ration of adalimumab therapy CD/UC: 157.8/70.1 weeks) were en-
rolled in this consecutive cohort from two referral IBD centres in
Hungary. Demographic data were comprehensively collected and a
harmonized monitoring strategy was applied. Previous and current
therapy, laboratory data and clinical activity at the time of the TL
and ADAmeasurement were recorded. Patients were evaluated either
at the time of suspected LOR or during follow-up. TDM measure-
ments were done by commercial ELISA (LISA TRACKER, Thera-
diag, France).
Results: Among 112 IBD patients, LOR/drug persistence was
25.9%/74.1%.The probability of ADA positivity and low TL (<4.0
μg/mL) was 12.1% and 17.8% in the first year and 17.3% and
29.5% and in the second year after start of adalimumab therapy
in Kaplan-Meier analysis. Dose intensification was needed in 29.5%
during the study period. There was an association between female
gender, ADA positivity and LOR (female gender: p<0.001, OR:
7.770 CI95%: 2.483–24.315, ADA positivity: p=0.007 OR: 3.616
CI95%: 1.374–9.518)), while no other parameters, including TL was
associated with LOR or dose intensification.
Table 1. ADA and TL status in IBD patients treated with adalimumab
Normal TL Low TL
ADA negative 58% 21.4%
ADA positive 10.7% 9.8%
Conclusions: Our results suggest that ADA development, low TL
and need for dose intensification are frequent during adalimumab
therapy and support the use of routine TDM assessment in IBD pa-
tients. Female gender, and ADA positivity were predictors of loss of
response.
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Background: The monitoring of appropriateness, costs, and clinical
outcomes of biological therapy in inflammatory bowel disease (IBD)
is a relevant need. We aimed to evaluate all these issues in Sicily
through a web based network of all prescribing centers.
Methods: From January 2013, all IBD patients starting a biological
agent (incident cases) or already on treatment (prevalent cases) were
entered in a web based software. Herein we report data of incident
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cases about the efficacy of biological therapy after twelve weeks and
one year of treatment.
Results: From January 2013 to October 2016, 1475 patients were
included. Incident cases were 1090. Considering that 16% of pa-
tients experienced more than one line of therapy, a total of 1351
treatments were reported. Adalimumab was used in 622 Crohn’s
disease (CD) patients and in 83 ulcerative colitis (UC)/unclassified
colitis patients. Infliximab was prescribed in 275 CD patients (80
biosimilars) and in 279 UC patients (50 biosimilars). Golimumab
was used in 32 UC patients, while vedolizumab in 40 CD patients
and in 20 UC patients. In patients with CD, after twelve weeks and
one year of therapy, the rates of remission with adalimumab were
43.9% and 60.2%, respectively, and the rates of response 40.9%
and 25.8%, while the rates of remission with infliximab originator
were 46.2% and 50.0%, and the rates of response 40.9% and 32.9%
(biosimilars: remission 31.0% and response 51.7% after 12 weeks;
remission 45.5% and response 36.4% after one year). In UC, after
twelve weeks and one year of therapy, the rates of remission with
adalimumab were 43.3% and 57.1%, respectively, and the rates of
response 36.7% and 19.0%; the rates of remission with infliximab
originator were 41.6% and 48.4%, and the rates of response 35.6%
and 32.3% (biosimilars: remission 30.0% and response 63.3% after
12 weeks; remission 20.0% and response 40.0% after one year); the
rate of remission after 12 weeks of therapy with Golimumab was
22.2%, and the rate of response was 33.3%. After twelve weeks of
therapy with Vedolizumab, 28.6% of CD patients were in remission
and 32.0% had a response, while the rates of remission and response
in UC patients were 33.3% and 22.0%, respectively. Multivariable
logistic regression analysis showed that age >50 years was indepen-
dently linked to lower rates of remission/response at 12 weeks in CD
patients (OR 0.613, p=0.046).
Conclusions: In one of the largest series of IBD patients on biological
therapy reported to date, CD patients older than 50 years showed a
higher rate of non response at 12 weeks of treatment. Efficacy of
biosimilars was overall comparable to that reported for infliximab
originator.
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Background: Despite data reporting that exclusive enteral nutrition
(EEN) improves nutritional status and inflammation in patients with
Crohn’s disease, few studies have reported its systematic use in the
perioperative setting. EEN involves the use of a liquid nutrition for-
mula to meet all of an individual’s dietary requirements. We sought
to test the hypothesis that EEN provides a safe and effective bridge
to surgery and reduces post-operative complications in adult patients
with Crohn’s disease requiring urgent surgery for stricturing or pen-
etrating complications.
Methods: Fifty-one patients who were treated with EEN prior
to planned surgery for stricturing or penetrating complications
of Crohn’s disease were identified from our specialist dietician’s
database. Thirty eight out of these fifty-one patients had surgery and
they were each matched with two control patients for disease be-
haviour, type of surgery, age at diagnosis and disease duration. Data
on disease phenotype, nutritional status, operative course, and post-
operative complications were obtained.
Results: Clinical status improved in 25% [13/51] of the EEN pa-
tients such that they no longer required surgery. EEN had no ef-
fect on pre-operative weight, but it significantly reduced median [in-
terquartile range (IQR)] serum CRP levels (baseline 36 [13–91] vs.
pre-operation 8 [4–31] mg/L, p=0.02). The median [IQR] length of
surgery was shorter in patients pre-optimised with EEN than controls
(3.0 [2.5–3.5] vs. 3.5 [3.0–4.0] hours respectively, p<0.001). Multi-
variable logistic regression analysis confirmed that going straight-to-
surgery compared with EEN pre-optimisation was associated with a
nine-fold increase in the incidence of post-operative abscess and/or
anastomotic leak (OR 9.1 95% CI [1.2–71.2], p=0.04).
Conclusions: EEN in adult patients presenting with stricturing or
penetrating complications of Crohn’s disease is associated with a re-
duction in systemic inflammation, operative times and the incidence
of post-operative abscess or anastomotic leak. Further controlled tri-
als are needed to elucidate how EEN may improve operative out-
comes and to confirm that EEN provides a safe and effective bridge
to surgery.
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Background: Vedolizumab (VDZ) has proven as an effective medi-
cation in adult Inflammatory Bowel Disease (IBD). There has been
increased off-label use of VDZ also in children but with very limited
published experience. Therefore we aimed to describe the short-term
effectiveness and safety of VDZ in children with IBD in the largest
pediatric cohort to date.
Methods: Retrospective review of children (2–18 years) treated with
VDZ from 17 centers affiliated with the Paediatric IBD Porto group
of ESPGHAN. Baseline characteristics and explicit prior and current
clinical data were recorded on a standardized REDcap case-report
forms. Primary outcome was treatment success at week 14 and last
follow-up, defined as steroid-free remission (i.e. wPCDAI<12.5 or
PUCAI<10) without the need for new medications or surgical inter-
vention. Safety data were also explicitly recorded.
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